Last reviewed · How we verify
Dichlorphenamide (open-label)
Dichlorphenamide inhibits carbonic anhydrase to reduce aqueous humor production and intraocular pressure.
Dichlorphenamide inhibits carbonic anhydrase to reduce aqueous humor production and intraocular pressure. Used for Primary angle-closure glaucoma or ocular hypertension (Phase 3 trial context).
At a glance
| Generic name | Dichlorphenamide (open-label) |
|---|---|
| Also known as | Daranide |
| Sponsor | University of Rochester |
| Drug class | Carbonic anhydrase inhibitor |
| Target | Carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Dichlorphenamide is a carbonic anhydrase inhibitor that decreases the production of aqueous humor in the eye by inhibiting the enzyme carbonic anhydrase in the ciliary body. This reduction in aqueous humor production leads to lower intraocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension management. It is a topical or systemic agent used to prevent vision loss associated with elevated intraocular pressure.
Approved indications
- Primary angle-closure glaucoma or ocular hypertension (Phase 3 trial context)
Common side effects
- Paresthesia
- Altered taste
- Fatigue
- Metabolic acidosis
- Hypokalemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dichlorphenamide (open-label) CI brief — competitive landscape report
- Dichlorphenamide (open-label) updates RSS · CI watch RSS
- University of Rochester portfolio CI